All In Biotech

Drug Trial Radar · NCT05755048

FS-1502 Versus T-DM1 for HER2-Positive Unresectable Locally Advanced or Metastatic Breast Cancer

A Multicenter, Open-label, Randomized Controlled Phase III Clinical Study to Compare the Efficacy and Safety of FS-1502 Versus T-DM1 in Patients With HER2-positive Unresectable Locally Advanced or Metastatic Breast Cancer

Last checked: Nov 19, 2026Latest source record: Sep 1, 2023 (this record)Source: ClinicalTrials.govMethods & limitations

Status unknownPivotal-lookingPhase 3. Randomized with 314 participants. This is a heuristic, not a regulatory label.

Status

Status unknown

Enrollment

314

Planned (sponsor's estimate)

Start

Mar 28, 2023

Primary completion

Jul 30, 2025

Study completion Jan 31, 2026

Sponsor

Sponsor type
Industry
First posted
Mar 6, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study is designed to compare the anti-tumor activity as well as the safety and efficacy of FS-1502 versus T-DM1 in HER2-positive, unresectable locally advanced or metastatic breast cancer subjects previously treated with trastuzumab and taxane.

Conditions

  • Breast Cancer

Interventions

  • Investigational drug: Recombinant Anti-HER2 Humanized Monoclonal Antibody - Monomethyl Auristatin F Conjugates for Injection (FS-1502)Biological

    Experimental: FS-1502 Dosage form: lyophilized powder Specification: 30 mg/vial Dose: 2.3 mg/kg, once every 3 weeks, 21 days as a cycle; Method of administration: intravenous drip.

  • Control drug: Trastuzumab emtansine (Kadcyla, T-DM1)Biological

    Active Comparator: Trastuzumab Emtansine (T-DM1) Trade name: Kadcyla Dosage form: lyophilized powder Specification: 100 mg/vial Dose: 3.6 mg/kg, once every 3 weeks, 21 days as a cycle; Method of administration: intravenous drip (this drug has been approved for marketing. Please refer to the package insert for details).

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Progression-Free Survival (PFS) Based on Independent Central Review (ICR) in Participants With HER2-Positive, Unresectable locally advanced or Metastatic Breast Cancer Previously Treated With Trastuzumab and Taxane.Time frame: Up to 28 months.

Locations

56 sites in 1 country. Site status is shown where the registry gives one.

  • The first affiliated hospital of bengbu medical college

    Bengbu, Anhui, China · Recruiting

  • Anhui Provincial Cancer Hospital

    Hefei, Anhui, China · Recruiting

  • Chinese People's Liberation Army General Hospital fifth Medical Center South ward

    Beijing, Beijing Municipality, China · Recruiting

  • Peking University People's Hospital

    Beijing, Beijing Municipality, China · Recruiting

  • Affiliated Cancer Hospital of Chongqing University

    Chongqing, Chongqing Municipality, China · Recruiting

  • Chinese People's Liberation Army Army Special Medical Center

    Chongqing, Chongqing Municipality, China · Recruiting

  • Fujian Cancer Hospital

    Fuzhou, Fujian, China · Recruiting

  • Fujian Medical University Union Hospital

    Fuzhou, Fujian, China · Recruiting

  • The 900th Hospital of the Joint Logistics Support Force of the Chinese People's Liberation Army

    Fuzhou, Fujian, China · Recruiting

  • The first affiliated hospital of xiamen university

    Xiamen, Fujian, China · Recruiting

  • The first Hospital of lanzhou University

    Lanzhou, Gansu, China · Recruiting

  • Guangdong Provincial People's Hospital

    Guangzhou, Guangdong, China · Recruiting

  • Sun Yat-sen University Cancer Center

    Guangzhou, Guangdong, China · Recruiting

  • The First Affiliated Hospital,Sun Yat-sen University

    Guangzhou, Guangdong, China · Recruiting

  • Shantou University School of Medicine Affiliated Cancer Hospital

    Shantou, Guangdong, China · Recruiting

  • Cancer Hospital Chinese Academy of Medical Sciences,Shenzhen Center

    Shenzhen, Guangdong, China · Recruiting

  • Guangxi Medical Univesity Cancer Hospital

    Nanning, Guangxi, China · Recruiting

  • The First Afeliated Hospital of Guangxi Medical University

    Nanning, Guangxi, China · Recruiting

  • Affiliated Hospital of Hebei University

    Baoding, Hebei, China · Recruiting

  • Cangzhou Central Hospital

    Cangzhou, Hebei, China · Recruiting

  • The Fourth Hospital of Hebei Medical University

    Shijiazhuang, Hebei, China · Recruiting

  • Harbin Medical University Cancer Hospital

    Harbin, Heilongjiang, China · Recruiting

  • AnYang Cancer Hospital

    Anyang, Henan, China · Recruiting

  • The First Affiliated Hospital of Xinxiang Medical University

    Xinxiang, Henan, China · Recruiting

  • Henan Provincial People's Hospital

    Zhengzhou, Henan, China · Recruiting

  • Renmin Hospital Of Wuhan University

    Wuhan, Hubei, China · Recruiting

  • Union Hospital, Tongji Medical College, Huazhong University of Science and Technology

    Wuhan, Hubei, China · Recruiting

  • Zhongnan Hospital of Wuhan University

    Wuhan, Hubei, China · Recruiting

  • Xiangyang Central Hospital

    Xiangyang, Hubei, China · Recruiting

  • The Second Xiangya Hospital, Central South University

    Changsha, Hunan, China · Recruiting

  • Chenzhou No.1 People's Hospital

    Chenzhou, Hunan, China · Recruiting

  • The Central Hospital of Yongzhou

    Yongzhou, Hunan, China · Recruiting

  • Jiangsu Cancer Hospital

    Nanjing, Jiangsu, China · Recruiting

  • Jiangsu Province Hospital

    Nanjing, Jiangsu, China · Recruiting

  • The Affiliated Hospital of Xuzhou Medical University

    Xuzhou, Jiangsu, China · Recruiting

  • Nanchang People's Hospital

    Nanchang, Jiangxi, China · Recruiting

  • First Hospital of Jilin University

    Changchun, Jilin, China · Recruiting

  • Jilin Cancer Hospital

    Changchun, Jilin, China · Recruiting

  • The Second Affiliated Hospital of Dalian Medical University

    Dalian, Liaoning, China · Recruiting

  • Liaoning cancer hospital & institute

    Shenyang, Liaoning, China · Not yet recruiting

Showing 40 of 56 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.